Wall Street analysts predict that BioLife Solutions Inc (NASDAQ:BLFS) will post $5.19 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for BioLife Solutions’ earnings. The lowest sales estimate is $5.00 million and the highest is $5.31 million. BioLife Solutions posted sales of $2.96 million during the same quarter last year, which suggests a positive year over year growth rate of 75.3%. The company is scheduled to report its next quarterly earnings report on Thursday, November 8th.

According to Zacks, analysts expect that BioLife Solutions will report full-year sales of $19.66 million for the current financial year, with estimates ranging from $19.10 million to $19.98 million. For the next financial year, analysts forecast that the business will report sales of $28.11 million, with estimates ranging from $26.00 million to $30.22 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover BioLife Solutions.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Thursday, August 9th. The medical equipment provider reported $0.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.01. BioLife Solutions had a return on equity of 2.24% and a net margin of 1.76%. The firm had revenue of $5.18 million for the quarter, compared to the consensus estimate of $5.20 million.

A number of research firms recently weighed in on BLFS. BidaskClub downgraded BioLife Solutions from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 7th. B. Riley set a $22.00 target price on BioLife Solutions and gave the stock a “buy” rating in a research report on Wednesday, October 3rd. Northland Securities reiterated a “buy” rating and set a $18.00 target price on shares of BioLife Solutions in a research report on Friday, August 10th. Maxim Group reiterated a “buy” rating and set a $26.00 target price on shares of BioLife Solutions in a research report on Wednesday, September 5th. Finally, ValuEngine downgraded BioLife Solutions from a “strong-buy” rating to a “buy” rating in a research report on Thursday, September 27th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $22.00.

In other news, CFO Greef Roderick De sold 10,000 shares of the business’s stock in a transaction on Wednesday, October 17th. The stock was sold at an average price of $12.95, for a total value of $129,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joseph C. Schick sold 4,765 shares of the business’s stock in a transaction on Friday, August 24th. The stock was sold at an average price of $25.96, for a total value of $123,699.40. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $259,600. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 95,385 shares of company stock worth $1,836,984. 38.50% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can acquired a new position in shares of BioLife Solutions in the second quarter worth $114,000. Kovack Advisors Inc. acquired a new position in shares of BioLife Solutions in the second quarter worth $126,000. OppenheimerFunds Inc. acquired a new position in shares of BioLife Solutions in the second quarter worth $130,000. Jane Street Group LLC acquired a new position in shares of BioLife Solutions in the second quarter worth $173,000. Finally, Shepherd Kaplan Krochuk LLC acquired a new position in shares of BioLife Solutions in the second quarter worth $183,000. 27.70% of the stock is owned by institutional investors.

Shares of BioLife Solutions stock traded down $0.32 during trading on Friday, reaching $12.41. The company’s stock had a trading volume of 78,500 shares, compared to its average volume of 213,850. BioLife Solutions has a 12-month low of $4.63 and a 12-month high of $26.35. The company has a market cap of $218.28 million, a PE ratio of -60.76 and a beta of 1.51.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.

Featured Story: Stock Symbols Definition, Examples, Lookup

Get a free copy of the Zacks research report on BioLife Solutions (BLFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.